EU 'Newmood' research investigating genetic links to treat depression with new drugsJune 29, 2004120 million people worldwide suffer from depression. An EU-funded research project launched recently will help to uncover the genetic factors linked to depression to develop new drug treatments. The Integrated Project, named NEWMOOD, has received EUR7.2 million in funding from the EU's Sixth Research Framework Programme (FP6) and aims to identify genes involved in triggering depression. This will help researchers to develop new drugs over the next five years to treat it and improve understanding of its causes. The drugs are set to revolutionise antidepressant drugs, which have not changed much over the past 30 years. The project, co-ordinated by the University of Manchester (United Kingdom) involves partners from 13 laboratories in 10 European countries including Estonia, France, Germany, Hungary, Italy, the Netherlands, Poland, Slovenia and Spain. "Depression is a widespread issue and represents a serious health problem in Europe. Everybody can feel sad. But depression is a severe and long-term problem where people feel hopeless and their professional and private life is hampered," says European Research Commissioner Philippe Busquin. "Traditional drugs mainly target brain chemicals, and are only partially effective. By looking into the genetics of depression EU researchers can go to the very roots of the illness, and help prevent and cure it in innovative ways. European scientists working together can make a difference and achieve a quantum leap in the fight against depression". Feeling blue Depression, which is marked by symptoms of reduced interest and pleasure, weight and appetite changes, agitation and fatigue, is believed to be caused by genetic and environmental factors. Chronic stress, such as long term illness or bereavement, can trigger depression in those genetically predisposed to the condition. Counselling is often used alongside drug treatment, but the NEWMOOD research hopes to find more effective drug treatments by identifying genes affecting depression in mice and rats, and later in humans. New drugs to take effect sooner Currently, most antidepressants work by boosting levels of serotonin in the brain, a chemical that allows nerve cells in the brain to communicate with one another. However, such treatments can take weeks to have an effect and only work in around 50% of patients. It is hoped the new drugs will be more effective and quicker to take effect. Targeting and understanding depression This gene research will help to provide new targets for the drugs and improve understanding of the key causes of depression. Researchers will develop a microchip carrying 800 genes to test which ones are active in healthy and depressed animals and humans. They will test the effects of these depression-related genes by altering their activity in genetically modified mice. Animal depression can be observed in mice by lower than usual interest in sweetened water and a tendency not to struggle as much when suspended from their tails. | |||||||||||||||||||||
|
Related Depression Current Events and Depression News Articles Astrocytes and synaptic plasticity By mopping up excess neurotrophic factor from neuronal synapses, astrocytes may finely tune synaptic transmission to affect processes such as learning and memory, say Bergami et al. Has a new era of reinstitutionalization in mental health care begun? A retrospective analysis of hospital episode statistics, involuntary admissions under the Mental Health Act 1983, and the number of psychiatric beds in England 1996-2006. Compassion meditation may improve physical and emotional responses to psychological stress Data from a new study suggests that individuals who engage in compassion meditation may benefit by reductions in inflammatory and behavioral responses to stress that have been linked to depression and a number of medical illnesses. Millisecond brain signals predict response to fast-acting antidepressant Images of the brain's fastest signals reveal an electromagnetic marker that predicts a patient's response to a fast-acting antidepressant, researchers have discovered. Bullying of teenagers online is common, UCLA psychologists report Nearly three in four teenagers say they were bullied online at least once during a recent 12-month period, and only one in 10 reported such cyber-bullying to parents or other adults, according to a new study by UCLA psychologists. Getting help for depression and anxiety has significant long-term benefits According to the Mood Disorder Society of Canada, about 1.3 million Canadians suffer from depression. Smoking increases depression in women, study reveals Researchers from the University of Melbourne and Barwon Health assessed a group of 1043 Australian women, whose health had been monitored for a decade as part of the Geelong Osteoporosis Study. Learning to shape your brain activity A study in the Oct. 1 issue of the journal Sleep shows that the successful manipulation of sensorimotor rhythm (SMR) amplitude by instrumental SMR conditioning (ISC) improved sleep quality as well as declarative learning. ISC might thus be considered a promising non-pharmacological treatment for primary insomnia. Adolescent insomnia linked to depression and substance abuse during adolescence and young adulthood A study in the Oct. 1 issue of the journal Sleep shows that adolescent insomnia symptoms are associated with depression, suicide ideation and attempts, and the use of alcohol, cannabis and other drugs such as cocaine. MS patients have higher spinal fluid levels of suspicious immune molecule A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease. More Depression Current Events and Depression News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||